IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- PTX-200 Breast Cancer Trial Progresses
- Steven Yatomi-Clarke Appointed CEO
- December 2015 Appendix 4C - Quarterly
- Virax secures $3 million placement
- Virax close out of VIR201 HIV Vaccine Phase IIa Trial
Later from Prescient Therapeutics
All Prescient Therapeutics news releasesFollow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics